Tibet Rhodiola Pharmaceutical Holding

Tibet Rhodiola Pharmaceutical Holding Forward P/E

The Forward P/E Ratio of Tibet Rhodiola Pharmaceutical Holding (600211.SS) as of Nov 5, 2026 is 14.34. In the previous year, Forward P/E Ratio was 12.80 — a change of 12.09% (higher).

Forward P/E

14.34

YoY

12.09%

Last updated:

Forward P/E Ratio of Tibet Rhodiola Pharmaceutical Holding is 2025 14.34 . Forward P/E Ratio of Tibet Rhodiola Pharmaceutical Holding was 2024 12.80 . It decreases by 12.09% higher compared to the previous year.

The Tibet Rhodiola Pharmaceutical Holding Forward P/E history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Forward P/E
Date
Forward P/E
Jan 1, 2018
62.40 CNY
Jan 1, 2019
43.08 CNY
Jan 1, 2020
32.18 CNY
Jan 1, 2021
64.39 CNY
Jan 1, 2022
36.38 CNY
Jan 1, 2023
16.80 CNY
Jan 1, 2024
12.80 CNY
Jan 1, 2025
14.34 CNY
The Tibet Rhodiola Pharmaceutical Holding Forward P/E history
YEARForward P/EYoY
14.34+12.09%
12.80-23.82%
16.80-53.82%
36.38-43.51%
64.39+100.11%
32.18-25.30%
43.08-30.97%
62.40+6.51%
58.58-13.65%
67.85-53.79%
146.82-77.11%
641.26—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Tibet Rhodiola Pharmaceutical Holding Stock analysis

What does Tibet Rhodiola Pharmaceutical Holding do? Tibet Rhodiola Pharmaceutical Holding Co. generates revenue through the manufacture and wholesale of pharmaceutical products. The company distributes proprietary drug products and processes pharmaceuticals, serving markets across South China, North China, East China, Central China, and overseas regions. Its primary customers are pharmaceutical distributors and healthcare providers within these regions, focusing on the distribution of its proprietary drug portfolio. The firm's revenue streams are derived from the wholesale of manufactured pharmaceuticals and the processing of pharmaceutical products. It operates through a network of distributors in key Chinese regions and overseas markets, targeting healthcare institutions and pharmacies that require its proprietary drug solutions. The company's business model emphasizes regional distribution networks to reach its target segments efficiently. Tibet Rhodiola Pharmaceutical Holding Co. relies on its proprietary drug products for sales, with a strong presence in multiple Chinese regions and overseas markets. The company's revenue is driven by the distribution of these products through its established wholesale channels, catering to the healthcare sector's demand for pharmaceutical solutions in its operational areas. Tibet Rhodiola Pharmaceutical Holding is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Tibet Rhodiola Pharmaceutical Holding stock

Forward P/E Ratio of Tibet Rhodiola Pharmaceutical Holding is 14.34 in 2025.

Forward P/E Ratio of Tibet Rhodiola Pharmaceutical Holding changed from 12.80 to 14.34, representing a 12.09% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Forward P/E Ratio Tibet Rhodiola Pharmaceutical Holding since 2006 – with annual values, charts, and detailed analysis.

The Forward P/E uses estimated future earnings to value a stock. A lower forward P/E relative to the trailing P/E suggests analysts expect earnings growth.

To evaluate Forward P/E Ratio's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Forward P/E Ratio.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Forward P/E Ratio's Tibet Rhodiola Pharmaceutical Holding with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Tibet Rhodiola Pharmaceutical Holding

All Key Metrics — Tibet Rhodiola Pharmaceutical Holding